key: cord-0272377-rv40va03
authors: Swanson, Olivia; Rhodes, Brianna; Wang, Avivah; Xia, Shi-Mao; Melissa, Cooper; Parks, Robert; Sanzone, Aja; Louder, Mark K.; Lin, Bob C.; Doria-Rose, Nicole A.; Saunders, Kevin O.; Bonsignori, Mattia; Wiehe, Kevin; Haynes, Barton F.; Azoitei, Mihai L.
title: Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations
date: 2021-01-14
journal: bioRxiv
DOI: 10.1101/2021.01.04.425252
sha: 5096e2e90836d330b0ab5f840bc3770b20ade770
doc_id: 272377
cord_uid: rv40va03

Elicitation of broadly neutralizing antibodies (bnAbs) by an HIV vaccine will involve priming the immune system to activate antibody precursors, followed by boosting immunizations to select for antibodies with functional features required for neutralization breadth. The higher the number of mutations necessary for function, the more convoluted are the antibody developmental pathways. HIV bnAbs acquire a large number of somatic mutations, but not all mutations are functionally important. Here we identified a minimal subset of mutations sufficient for the function of to the naturally occurring, more mutated V3-glycan bnAb DH270.6. Using antibody library screening, candidate envelope immunogens that interacted with DH270.6-like antibodies containing this set of key mutations were identified and selected in vitro. Our results demonstrate that less complex B cell evolutionary pathways than those naturally observed exist for the induction of HIV bnAbs by vaccination, and establish rational approaches to identify boosting sequential envelope candidate immunogens.

the only branch that gives rise to bnAbs acquired a rare tyrosine to proline mutation that is 56 essential for broad neutralizing activity (Shen et al., 2020) . Since improbable functional 57 mutations represent rare events that restrict bnAb development, antibodies with such sequence 58 changes will likely need to be explicitly selected by candidate immunogens in vaccinations. 59

Significant progress has been made in the design of immunogens that activate 3 alternate amino acids of higher probability were identified. Taken together, these results show 346 that diverse amino acids that occur with higher probability in vivo are functionally equivalent to 347 the native ones present at the key DH270.6 paratope sites. Therefore, multiple, more accessible 348 pathways than the one naturally observed may exist to induce DH270.6-like antibodies by 349 vaccination. 350

A major task of current HIV vaccine development efforts is to design successful 352 sequential immunogen regimens capable of binding to B cell receptors of bnAb lineage 353 members that have functional improbable mutations required for potent bnAb activity. Here we 354 report a rapid strategy for identification of the minimal functional mutations needed for antibody 355 breadth and the identification of HIV Envs as sequential immunogen candidates that bind to 356 bnAb lineage BCRs. Our results show that only a small number of acquired mutations are 357 necessary for the development of DH270.6 V3-glycan bnAb precursors into broadly neutralizing 358 antibodies. Twelve amino acid changes from UCA were sufficient to recapitulate 90% of 359 DH270.6 neutralization. While the majority of these mutations were located in the paratope, 360 three of them did not directly contact HIV Env. Therefore, residues away from the binding site 361 also modulate function, likely by affecting the antibody conformation or stability (Klein et al., Recently, a "minimized" BG18 was described that preserves 22 out of the 60 acquired mutations 367 and recapitulates 66% of the neutralization breadth of the mature bnAb (Steichen et al., 2019) . 368 minBG18 contains only the acquired mutations located at the binding interface, while all the 369 amino acids located away from the paratope are reverted to their UCA identity. In comparison, 370 by considering acquired mutations outside the binding interface in our designs, DH270min11 371 almost fully recapitulates the breadth of DH270.6, while maintaining a lower percentage (28%) 372 of the total acquired mutations than minBG18 (36%). VRC01, a bnAb that targets the CD4 373 DH270.6-derived antibody containing only the naturally acquired probable mutations had no 399 neutralization ability. Since only a small number of sequence changes, but no insertions or 400 deletions, are required for the development of DH270.6-like bnAbs from germline precursors, 401 these antibodies are an attractive target for elicitation by vaccination. DH270min11 is only 8% 402 mutated from the DH270UCA, and represents to our knowledge one of the least mutated HIV 403 antibodies with broadly neutralizing capabilities (Simonich et al., 2016) . While DH270min11 404

should be easier to induce by vaccination than DH270.6, the presence of a large number of 405 improbable mutations may present a significant barrier for its elicitation. To address this 406 challenge, we aimed to identify non-native amino acids, predicted to occur with higher frequency 407 in vivo, at the key sites in DH270min11. High throughput library screening led to the 408 identification of other functionally equivalent amino acids that are expected to occur with higher 409 probability in vivo. At each of the 10 improbable sites in DH270min11 at least one other more 410

probable alternate amino acid was found, with 7 of 10 sites tolerating at least two such residues. 411

Thus, these results indicate that diverse developmental pathways exist for the elicitation of 412 DH270.6-like bnAbs, and that such pathways are more direct and expected to occur with higher 413 frequencies than those pathways naturally observed. Therefore, glycan-V3 targeting bnAbs that 414 resemble DH270.6/DH270min11 mAbs are an attractive HIV vaccine target. 415

Compared to previous HIV bnAb minimization studies, we leveraged our minimized 416 DH270 antibodies to find and characterize envelopes for the induction of similar antibodies by 417 vaccination. Our approach relied on the identification of proteins that preferentially interacted 418 with DH270.6-derived antibodies through mutations deemed essential for function. Diverse 419 molecular properties can control the ability of candidate immunogens to contact different 420 bnAbs that contain all but one of the acquired improbable mutations in DH270min11 ( Figure 6 ). 434

In order to more robustly select for the improbable acquired mutations M51HC, Y27LC and L48LC, 435 additional boosting immunogens may be required. Based on one available data set (Saunders 436 the envelope discovery and characterization approach presented here is primarily meant to 444 provide a rational way to classify and prioritize candidate immunogens for in vivo testing. The 445 potential of the vaccination regimen identified here to induce DH270.6-like bnAbs that contain 446

the key target mutations in vivo will be assessed in animal models in upcoming work. 447 identified that were deemed not important for DH270.6 stability or binding. The amino acids at 476 these sites were changed to their UCA identity and the Rosetta energy of the new antibodies 477 was computed. Upon reversion to UCA, 5000 Rosetta models were generated for each 478 "minimized" antibody decoys by sampling all amino acid side chains and allowing fine backbone Sequencing results by PacBio returned 35-47k reads per sample sequenced, of which 15-26k 537 aligned to the scFv amplicon. Sequencing data was processed using Geneious Prime and 538 programs developed in-house to compute the amino acid frequency and distribution. 539 Antibody expression and purification. Antibodies were expressed and purified as 540 previously described (Saunders et al., 2019) . Briefly, 100mL cultures of Expi293F cells at a 541 density of 2.5x10 6 cells/mL were transiently transfected with 50µg each heavy and light chain 542 encoding plasmids and Expifectamine (Invitrogen) per manufacturer's protocol. Five days after 543 transfection, cell culture media was cleared of cells by centrifugation, and the surpernatant was 544 filtered with 0.8 micron filters. Clarified supernatant was incubated with Protein A beads 545 (ThermoFisher) over night at 4C, washed with 20mM Tris supplemented with 350mM NaCl 546 (pH=7), followed by elution with a 2.5% Glacial Acetic Acid Elution Buffer and subsequent buffer 547 exchange into 25mM Citric Acid supplemented with125mM NaCl (pH=6). IgGs expression was 548 confirmed by reducing SDS-PAGE analysis, and quantified by measuring absorbance at 280nM 549 Signal was calculated as a reduction in luminescence compared to control wells and reported as 564 were blocked overnight at 4C. Starting concentrations of 100ug/mL purified antibody were 568 serially diluted 3-fold and incubated at room temperature for 1 hour. 1:30,000 HRP-conjugated 569 hIgG in assay diluent was added to plates, incubated for one hour, and developed using TMB 570 substrate. Plates were read at 450nm on a SpectraMax 384 PLUS reader (Molecular Devices). -01  >50  >50  >50  >50  >50  >50  >50  0013095-2.11  C  CVL2139_001-01  >50  >50  >50  >50  >50  >50  >50  001428-2.42 C CVL2139_001-02  >50  >50  >50  >50  >50  >50  >50  001428-2.42  C  CVL2139_001-02  >50  >50  >50  >50  >50  >50  >50  0077.v1.c16 C CVL2139_001-03  >50  >50  >50  >50  >50  >50  >50  0077.v1.c16  C  CVL2139_001-03  >50  >50  >50  >50  >50  >50  >50  00836-2.5 C CVL2139_001-04  >50  >50  >50  >50  >50  >50  >50  00836-2.5  C  CVL2139_001-04  >50  >50  >50  >50  >50  >50  >50  0921.v2.c14 C CVL2139_001-09  >50  >50  >50  >50  >50  >50  >50  0921.v2.c14  C  CVL2139_001-09  >50  >50  >50  >50  >50  >50  >50  16055-2.3 C CVL2139_001-10  >50  >50  >50  >50  >50  >50  >50  16055-2.3  C  CVL2139_001-10  >50  >50  >50  >50  >50  >50  >50 The binding of DH270min1 was measured to immunogen candidates by ELISA suggests an affinity gradient exists amongst the immunogen candidates. This correlates with previous data that these viruses are progressively more difficult to neutralize described in Supplementary  Figure 6 and supports the use of these immunogens in sequential prime/boost strategy. Figure 4D , individually plotted. Negative library enrichment values are plotted as 0. The enrichment of mutations by 10.17DT vaccination in mice and the enrichment of yeast library clones selected by 10.17DT (y-axis) plotted against heavy chain mutation. Library enrichment values were calculated as described in Figure 4C . For immunization enrichment, both the data from individual animals (gray, dashed) and the calculated average (blue) is displayed. Figure 6 . DH270min11 neutralization of pseudoviruses that containin the Envs used for the analysis of scFv libraries. Values indicate IC 50 neutralization values of DH270 lineage precursor antibodies and DH270min11 mAb against pseudoviruses containing Envs that were used to develop the immunogens described in Figures 3, 4 and 5 Figure 8 . The predicted probability of DH270min11 alternate amino acids to occur in vivo.

ARMADiLLO calculated probabilities of alternate amino acids identified at the key functional sites of DH270min11 by the library screening approach described in Figure 5 and Supplementary Figure 7 . Residues present in the mature DH270.6 together with their expected probability to occur in vivo are shown in blue.

Targeted selection of HIV-specific antibody mutations by engineering B 733 cell maturation

VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the 736 Maturation of a Broad HIV-Neutralizing Lineage

HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant

The effects of somatic hypermutation on neutralization and binding in the PGT121 family 741 of broadly neutralizing HIV antibodies

HIV Vaccine Design to Target Germline Precursors of 744

Glycan-Dependent Broadly Neutralizing Antibodies

A generalized HIV vaccine design strategy for priming of broadly 747 neutralizing antibody responses

Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is 750 Mimicked by a Soluble Trimeric Immunogen

Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires

Broad neutralization coverage of HIV by multiple highly potent 756 antibodies

Functional Relevance of Improbable Antibody Mutations for 759 HIV Broadly Neutralizing Antibody Development

Rational design of envelope identifies broadly neutralizing human monoclonal 762 antibodies to HIV-1

Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of 765 Chronic HIV-1 Infection

Models of somatic hypermutation targeting and 768 substitution based on synonymous mutations from high-throughput immunoglobulin sequencing data